Baxter International

Baxter to Host Fourth-Quarter 2023 Financial Results Conference Call for Investors

Retrieved on: 
Thursday, January 4, 2024
General Health, Health, Medical Supplies, Baxter International, Central Time, Webcast, Medtech

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2023 financial results on Thursday, February 8, 2024 at 7:30 a.m. Central Time.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2023 financial results on Thursday, February 8, 2024 at 7:30 a.m. Central Time.
  • To participate in this conference call please follow this link https://conferencingportals.com/event/etCeELhb to pre-register for the call and receive the call information.
  • This call is also being webcast and can be accessed through Baxter’s website at www.baxter.com .
  • The conference call will be recorded by Baxter and is copyrighted material.

Dr. Stephen Oesterle and Dr. Joshua Makower Join Patient Square Capital as Senior Advisors

Retrieved on: 
Thursday, January 4, 2024
Paragon, Acclarent, Mechanical engineering, Health, Yale School of Medicine, Stanford University, Patent, Biological engineering, SVP, Teleflex, Bard (company), Baxter International, MIT, American Institute, MBA, Columbia University, CeramTec, National academy, Mechanical, Yale school, Flexner Report, Friends, Therapy, Invention, Biomedicine, Patient, Harvard Medical School, Hospital, MD, Medtronic, Investment, Harvard College, Interventional cardiology, Nursing

MENLO PARK, Calif., Jan. 4, 2024 /PRNewswire/ -- Patient Square Capital , a leading health care investment firm, today announced that Dr. Joshua Makower and Dr. Stephen Oesterle joined as Senior Advisors to the firm.

Key Points: 
  • MENLO PARK, Calif., Jan. 4, 2024 /PRNewswire/ -- Patient Square Capital , a leading health care investment firm, today announced that Dr. Joshua Makower and Dr. Stephen Oesterle joined as Senior Advisors to the firm.
  • Dr. Makower will also be joining the board of Elevage Medical Technologies, a Patient Square portfolio company focused on growth-stage medical technologies.
  • "Dr. Oesterle and Dr. Makower are undisputed leaders, innovators, and investors in the medical technology space," said Neel Varshney, M.D., Founding Partner of Patient Square.
  • "The resources Patient Square has assembled for the ultimate goal of improving patient outcomes are transformational," added Dr. Oesterle.

TQRP: A Catalyst for Change and Educational Equity

Retrieved on: 
Tuesday, January 2, 2024
Booz Allen Hamilton, Walking, Learning, Student, Chemistry, Thurgood Marshall College, Thurgood Marshall College Fund, Education, Heart, General Motors, Booz, AdoptAClassroom.org, Equitable, Sneed, Nike, Baxter International, Teaching, STEM, Tutoring

TQRP is not just a program; it is a catalyst for change.

Key Points: 
  • TQRP is not just a program; it is a catalyst for change.
  • The success stories from this summer, such as that of Aniyah Sneed, exemplify the program’s transformative influence.
  • “The scholarship helped alleviate some of the burdens that I felt walking into my first year as a teacher,” Sneed said.
  • Additionally, the company distributed school supply kits during the 2023 TQRP Summer Institute Practicum at John Hayden Johnson Middle School.

Spectral Medical Provides Tigris Trial Update

Retrieved on: 
Thursday, December 14, 2023
Sepsis, EDEN, Septic shock, FDA, Mortality, Randomized controlled trial, Observational study, Lipopolysaccharide, PMX, TSX, Patient, Baxter International, Pharmaceutical industry

TORONTO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.

Key Points: 
  • TORONTO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.
  • Currently 20 Tigris trial sites, with near term onboarding of new, high quality clinical sites.
  • Clinical Trial Agreements (“CTA”) either executed or in final revision phase at six new clinical sites.
  • Dr. John Kellum, Chief Medical Officer of Spectral, commented, “Since the end of October, we experienced strong enrollment into Tigris despite the U.S. Thanksgiving holiday, with seven patient enrollments in the last eight weeks.

ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates

Retrieved on: 
Monday, November 13, 2023
Chronic kidney disease, Webcast, QP, Renal replacement therapy, GMP, Specialization, International, Physician, Kidney failure, Kidney disease, CVS Health, Risk, Surgeon, Glomerular filtration rate, Data, Patient, Framingham Heart Study, Dialysis, CKD, Boston University, Internal medicine, Baxter International, Albuminuria, Documentation, Health, Nephrology, Business administration, Conference, REACT, Trial of the century, EGFR, Quality of life, Memorial University of Newfoundland, Kellogg School of Management, Commercialization, Medical device, Pharmaceutical industry, Cryptocurrency

Positive interim Phase 2 data demonstrate the potential of REACT® to preserve kidney function in moderate and high-risk diabetic CKD patients.

Key Points: 
  • Positive interim Phase 2 data demonstrate the potential of REACT® to preserve kidney function in moderate and high-risk diabetic CKD patients.
  • Updated interim REACT RMCL-002 study data support continued investigation of REACT’s potential to benefit patients with moderate and high-risk diabetic CKD.
  • The ongoing Phase 2 clinical study assessed adverse events and changes in kidney function as measured by estimated glomerular filtration rate (eGFR), as primary study endpoints.
  • Further, you may listen to the presentation by dialing 1-877-407-0784 (US) or 1-201-689-8560 (International) and entering the Conference ID: 13742672.

Baxter Advances First Intravenous (IV) Bag Recycling Pilot for U.S. Hospitals

Retrieved on: 
Thursday, December 14, 2023
Recycling, Medical Supplies, Health, Medical Devices, Environment, Hospitals, Other Health, Syringe, NYSE, PVC, Carbon footprint, Baxter International, Nursing, Needle, Patient, Multimedia, Northwestern Memorial Hospital, Polyvinyl chloride, Baxter, Hospital, Northwestern Medicine

Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, announced the completion of the first phase of its intravenous (IV) bag recycling program pilot.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, announced the completion of the first phase of its intravenous (IV) bag recycling program pilot.
  • View the full release here: https://www.businesswire.com/news/home/20231214638041/en/
    Photo of IV bag recycling provided by Northwestern Medicine.
  • All IV bags involved in this pilot were made of PVC, one of the most widely used plastic materials in medical products.
  • In recent years, Baxter has introduced several programs to facilitate recycling for patients and hospitals in Australia, New Zealand, Guatemala and Colombia.

Baxter to Present at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, December 13, 2023
Health, Medical Devices, Hospitals, Practice Management, Managed Care, Pharmaceutical, Biotechnology, Medtech, Altrusa International, Inc, NYSE, Conference, Baxter International, Management

Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024.
  • José (Joe) E. Almeida, Baxter’s chairman, president and chief executive officer, is scheduled to present at 10:30 a.m. Pacific Time.
  • The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Friday, July 5, 2024.

Baxter Publishes Task Force on Climate-Related Financial Disclosures (TCFD) Report and Is Named to Dow Jones Sustainability Index North America

Retrieved on: 
Monday, December 11, 2023
Medical Supplies, Health, Medical Devices, Hospitals, Research, Science, Pharmaceutical, Disclosure, Carbon, Corporation, NYSE, Risk management, TCFD, Water, Baxter International, International Sustainability Standards Board, DJSI, Patient, Dow Jones, Climate, Corporate social responsibility, Sustainability Accounting Standards Board, Baxter, Medtech, Task force, Renewable energy

The publication of the TCFD report comes as Baxter is named to the Dow Jones Sustainability Index (DJSI) North America for 2023, recognizing the company’s leading sustainability efforts.

Key Points: 
  • The publication of the TCFD report comes as Baxter is named to the Dow Jones Sustainability Index (DJSI) North America for 2023, recognizing the company’s leading sustainability efforts.
  • Baxter has proudly been included in DJSI North America each year since it launched in 2005.
  • The TCFD report complements Baxter’s annual Corporate Responsibility Report , Sustainability Accounting Standards Board (SASB) Index and submissions to CDP Climate and CDP Water , as well as other environmental, social and governance-related disclosures.
  • Moving forward, Baxter expects to report against the TCFD framework in the company’s annual Corporate Responsibility Report.

The Baxter International Foundation and UNICEF Partner to Expand Access to Safe Water and Sanitation in Egypt

Retrieved on: 
Tuesday, November 28, 2023
Other Philanthropy, Utilities, General Health, Health, Energy, Medical Devices, Philanthropy, Foundation, Sanitation, Woman, Corporation, UNICEF USA, NYSE, Climate change, Baxter International, UN, Water cycle, Climate, Weather, Drinking water, Baxter, Rehabilitation, Child, Sustainable Development Goal 6, School, Hygiene, Mother, Water, Death, Partnership, Sewage, UNICEF, Environment, Life, Education, United Nations, WASH, Nursing, Renewable energy

The Baxter International Foundation, the philanthropic arm of Baxter International Inc. (NYSE:BAX), and UNICEF, today announced a partnership to improve access to safe drinking water and sanitation in five water-challenged regions in Egypt.

Key Points: 
  • The Baxter International Foundation, the philanthropic arm of Baxter International Inc. (NYSE:BAX), and UNICEF, today announced a partnership to improve access to safe drinking water and sanitation in five water-challenged regions in Egypt.
  • Baxter and the Baxter International Foundation actively invest in community-focused water projects to improve access to equitable and safe water and sanitation in water-stressed areas.
  • UNICEF and the Baxter International Foundation previously launched a program to improve water security in La Guajira, Colombia in 2021.
  • Through the programs in Egypt and Colombia, UNICEF and the Baxter International Foundation aim to support United Nations Sustainable Development Goal (UN SDG) 6, focusing on Clean Water and Sanitation.

Baxter Declares Quarterly Dividend

Retrieved on: 
Tuesday, November 14, 2023
Biotechnology, Medical Devices, Health, Pharmaceutical, Medical Supplies, NYSE, Baxter International, Holding company

Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock.
  • The dividend is payable on January 2, 2024, to shareholders of record as of December 1, 2023.
  • The indicated annual dividend rate is $1.16 per share of common stock.